[go: up one dir, main page]

CY1116000T1 - Υποκατεστημενες πυραζολες, συνθεσεις που τις περιεχουν, μεθοδος παραγωγης και χρηση - Google Patents

Υποκατεστημενες πυραζολες, συνθεσεις που τις περιεχουν, μεθοδος παραγωγης και χρηση

Info

Publication number
CY1116000T1
CY1116000T1 CY20151100068T CY151100068T CY1116000T1 CY 1116000 T1 CY1116000 T1 CY 1116000T1 CY 20151100068 T CY20151100068 T CY 20151100068T CY 151100068 T CY151100068 T CY 151100068T CY 1116000 T1 CY1116000 T1 CY 1116000T1
Authority
CY
Cyprus
Prior art keywords
compositions containing
manufacturing
substituted types
substituted
types
Prior art date
Application number
CY20151100068T
Other languages
English (en)
Inventor
Kirsten Bjergarde
Mark Dodson
Jacques Mauger
Anil Nair
Marcel Patek
Michel Tabart
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of CY1116000T1 publication Critical patent/CY1116000T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε νέες χημικές συνθέσεις, ιδίως σε υποκατεστημένες πυραζόλες, τις συνθέσεις που τις περιέχουν, και χρήση τους ως φάρμακα.
CY20151100068T 2006-11-10 2015-01-22 Υποκατεστημενες πυραζολες, συνθεσεις που τις περιεχουν, μεθοδος παραγωγης και χρηση CY1116000T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0609812A FR2908409B1 (fr) 2006-11-10 2006-11-10 Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
EP07870263.6A EP2091920B1 (fr) 2006-11-10 2007-11-09 Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation

Publications (1)

Publication Number Publication Date
CY1116000T1 true CY1116000T1 (el) 2017-01-25

Family

ID=38169388

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100068T CY1116000T1 (el) 2006-11-10 2015-01-22 Υποκατεστημενες πυραζολες, συνθεσεις που τις περιεχουν, μεθοδος παραγωγης και χρηση

Country Status (39)

Country Link
US (3) US7989439B2 (el)
EP (1) EP2091920B1 (el)
JP (1) JP5538893B2 (el)
KR (1) KR20090083456A (el)
CN (1) CN101553473B (el)
AR (1) AR063638A1 (el)
AU (1) AU2007327423B2 (el)
BR (1) BRPI0718999A2 (el)
CA (1) CA2667846A1 (el)
CL (1) CL2007003251A1 (el)
CO (1) CO6190516A2 (el)
CR (1) CR10749A (el)
CY (1) CY1116000T1 (el)
DK (1) DK2091920T3 (el)
DO (1) DOP2009000088A (el)
EA (1) EA019454B1 (el)
EC (1) ECSP099312A (el)
ES (1) ES2528385T3 (el)
FR (1) FR2908409B1 (el)
HN (1) HN2009000856A (el)
HR (1) HRP20150070T1 (el)
IL (1) IL198328A0 (el)
MA (1) MA30972B1 (el)
MX (1) MX2009004983A (el)
MY (1) MY147502A (el)
NI (1) NI200900078A (el)
NO (1) NO20091990L (el)
NZ (1) NZ576709A (el)
PE (2) PE20081162A1 (el)
PL (1) PL2091920T3 (el)
PT (1) PT2091920E (el)
SI (1) SI2091920T1 (el)
SV (1) SV2009003253A (el)
TN (1) TN2009000155A1 (el)
TW (1) TW200829556A (el)
UA (1) UA97965C2 (el)
UY (1) UY30707A1 (el)
WO (1) WO2008065282A2 (el)
ZA (1) ZA200903560B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858323B2 (en) * 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
FR2947546B1 (fr) * 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
TWI532725B (zh) * 2010-01-26 2016-05-11 賽諾菲阿凡提斯公司 經氧取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
TWI523844B (zh) * 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
CN102432639B (zh) * 2011-09-30 2013-11-06 山东大学 1-(2-羟基-3-(苯氨基)丙基)-3-二茂铁基-1h-吡唑-5-甲酸乙酯化合物及其应用
CA2888960C (en) 2012-11-02 2017-08-15 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CA2976766A1 (en) 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6706711B2 (en) * 2001-04-27 2004-03-16 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitor
BRPI0409427A (pt) * 2003-04-16 2006-04-18 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
EP2256106B1 (en) * 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
WO2006003440A1 (en) * 2004-07-05 2006-01-12 Astex Therapeutics Limited 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors
WO2006018662A2 (en) * 2004-08-16 2006-02-23 Prosidion Limited Aryl urea derivatives for treating obesity
EP1836188A1 (en) * 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
RU2007131101A (ru) * 2005-01-21 2009-02-27 Астекс Терапьютикс Лимитед (Gb) Комбинации пиразольных ингибиторов киназы и других средств против злокачественных новообразований
AR052660A1 (es) * 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
EP1683796A1 (en) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
FR2947546B1 (fr) * 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
HRP20150070T1 (hr) 2015-02-27
US7989439B2 (en) 2011-08-02
US20110237801A1 (en) 2011-09-29
CO6190516A2 (es) 2010-08-19
CN101553473B (zh) 2013-06-05
JP5538893B2 (ja) 2014-07-02
EP2091920A2 (fr) 2009-08-26
US8410286B2 (en) 2013-04-02
HN2009000856A (es) 2011-10-19
TW200829556A (en) 2008-07-16
CN101553473A (zh) 2009-10-07
NI200900078A (es) 2010-01-27
ECSP099312A (es) 2009-06-30
CR10749A (es) 2009-07-23
EP2091920B1 (fr) 2014-10-22
ES2528385T3 (es) 2015-02-09
MA30972B1 (fr) 2009-12-01
PE20121152A1 (es) 2012-09-07
UA97965C2 (ru) 2012-04-10
ZA200903560B (en) 2010-08-25
IL198328A0 (en) 2010-02-17
EA019454B1 (ru) 2014-03-31
WO2008065282A2 (fr) 2008-06-05
FR2908409A1 (fr) 2008-05-16
FR2908409B1 (fr) 2009-01-09
UY30707A1 (es) 2008-07-03
HK1137988A1 (en) 2010-08-13
SV2009003253A (es) 2009-10-27
AU2007327423A1 (en) 2008-06-05
TN2009000155A1 (fr) 2010-10-18
CA2667846A1 (fr) 2008-06-05
MX2009004983A (es) 2009-05-22
PT2091920E (pt) 2015-02-05
SI2091920T1 (sl) 2015-02-27
CL2007003251A1 (es) 2009-08-07
PL2091920T3 (pl) 2015-04-30
BRPI0718999A2 (pt) 2014-02-25
DOP2009000088A (es) 2013-06-15
MY147502A (en) 2012-12-14
KR20090083456A (ko) 2009-08-03
NZ576709A (en) 2011-08-26
DK2091920T3 (en) 2015-01-26
AR063638A1 (es) 2009-02-04
US20110237641A1 (en) 2011-09-29
NO20091990L (no) 2009-06-02
PE20081162A1 (es) 2008-10-02
WO2008065282A3 (fr) 2008-07-31
US8420824B2 (en) 2013-04-16
EA200970472A1 (ru) 2009-10-30
JP2010509297A (ja) 2010-03-25
AU2007327423B2 (en) 2012-09-06
US20090291984A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
CY1116000T1 (el) Υποκατεστημενες πυραζολες, συνθεσεις που τις περιεχουν, μεθοδος παραγωγης και χρηση
CY2024007I2 (el) Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζονιτριλιου, φαρμακευτικες συνθεσεις που περιεχουν τετοιες ενωσεις, η χρηση τους και μεθοδοι παρασκευης τους
CY1110926T1 (el) Υποκατεστημενες πυραζολο πυριδινες, συνθεσεις που τις περιεχουν, διαδικασια παρασκευης και χρηση
CY1110813T1 (el) Χημικες ενωσεις
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
CY1116264T1 (el) Αντισωματα κατα ανθρωπινης αγγειοποιητινης 2
CY1112305T1 (el) Σκευασμα που περιεχει μετφορμινη και βιλδαγλιπτινη
CY1116455T1 (el) Υποκατεστημενα 4-αρυλο-1,4-διυδρο-1,6-ναφθυριδιν αμιδια και η χρηση τους
NO20083153L (no) Kjemiske forbindelser
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
UY28350A1 (es) Productos aril-heteroaromaticos, composiciones que los contienen y su utilización
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
CY1113551T1 (el) Υποκατεστημενες ενωσεις νικοτιναμιδιου και η χρησιμοποιηση τους σε φαρμακα
EP2322574A4 (en) IONOMIC RESIN, RESIN COMPOSITIONS AND THE USE OF BOTH
CY1110891T1 (el) Παραγωγα 6-ετεροαρυλπυριδοϊνδολονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
CY1112121T1 (el) ΠΑΡΑΓΩΓΑ ΤΩΝ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-[1,2-α]-ΠΥΡΑΖΙΝ-6-ΚΑΡΒΟΞΑΜΙΔΙΩΝ ΚΑΙ ΤΩΝ 2,3,4,5-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-(1,2-α)-ΔΙΑΖΕΠΙΝ-7-ΚΑΡΒΟΞΑΜΙΔΙΩΝ, Η ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ ΚΑΙ Η ΕΦΑΡΜΟΓΗ ΤΟΥΣ ΣΕ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ
ATE483720T1 (de) Verbindungen enthaltend organofluorochlorophosphatanionen
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
EA201100657A1 (ru) Стеклянное изделие с улучшенной химической стойкостью
TW200744612A (en) New combination
NO20091386L (no) Fenyloksyanilinderivater
CY1108865T1 (el) Υποκατεστημενες 2,5-διαμινομευθυλο-1η-πυρρολες